Small increase in risk with prostate radiation
Receiving radiation for prostate cancer increases the risk of other cancers very slightly, Stanford Medicine researchers find, allowing providers to better inform patients weighing treatment options.
Targeting enzyme that fuels cancer cells
Stanford Medicine researchers have created a molecule that blocks an enzyme thought to be instrumental in causing colon cancer relapse or chemotherapy resistance.
$13 million for cancer research
The funding, from Cancer Grand Challenges, will help the researchers address difficult problems in cancer prevention, treatment-resistant cancers and therapies for pediatric solid tumors.
COVID-19 brain fog similar to chemo brain
Researchers found that damage to the brain’s white matter after COVID-19 resembles that seen after cancer chemotherapy, raising hope for treatments to help both conditions.
Cancer disparities in Pacific Islanders
Native Hawaiians and other Pacific Islanders experience poorer breast cancer survival outcomes that are hidden when their data is included in Asian populations, Stanford researcher says.
‘Remote-controlled’ CAR-T cell therapy safer
Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug. The modified cells are safer, more potent and more active against solid tumors in mice.
New therapies for rare blood cancer
Hematologist Jason Gotlib wanted more effective treatments for patients with systemic mastocytosis. His research has led to the approval of two new treatments by the Food and Drug Administration.
Key molecule’s structure found at last
The structure of a critical cellular-signaling molecule has finally been discovered by Stanford researchers. The finding may lead to new therapies.
Cancer drugs might be used to treat TB
Tuberculosis lesions in the lungs have high levels of proteins that suppress the immune system. Cancer drugs that target these proteins could be used to fight the bacterial infection.
Cancer drug renders COVID vaccine ineffective
Rituximab, a drug widely used in patients with lymphoma, blunts or eliminates the antibody response to COVID-19 vaccines if it is administered before them, Stanford researchers say.
Antibody synergy targets tough cancers
Two anti-cancer antibodies have a much stronger effect against pediatric nerve-cell and bone cancers in mice than either one alone, researchers have discovered.
- Big Data
- Cardiovascular Health
- Chemical Biology
- Chronic Disease
- Developmental Biology
- Global Health
- Health Policy
- Infectious Disease
- Mental Health
- Patient Care
- Precision Health
- Preventive Medicine
- Stem Cells
- Women's Health